Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoid Leukemia (ALL)Myelodysplastic Syndromes (MDS)
- Interventions
- Other: Personalized rATG (P-rATG)Radiation: Hyper fractionated total body irradiationDrug: GCSF
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT04872595
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Itacitinib for the Prevention of Graft Versus Host Disease
- Conditions
- Hematologic and Lymphocytic Disorder
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04859946
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- Conditions
- Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 324
- Registration Number
- NCT04708054
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Embryonal CarcinomaMalignant TeratomaChoriocarcinomaMixed Germ Cell TumorPineal Region Germ Cell TumorCentral Nervous System Nongerminomatous Germ Cell TumorImmature TeratomaSuprasellar Germ Cell TumorPineal Region Immature TeratomaPineal Region Yolk Sac Tumor
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look Surgery
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Blank Children's Hospital, Des Moines, Iowa, United States
IS-free Treg HaploHCT
- Conditions
- Stem Cell Transplant ComplicationsGraft Vs Host DiseaseMyeloid Leukemia, AcuteMyeloid Leukemia in Relapse (Disorder)Myelodysplastic Syndromes
- Interventions
- Radiation: RadiationBiological: Treg-enriched donor cellBiological: Unmodified donor T CellProcedure: CD34+ Haplo Peripheral Blood Stem Cell
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04678401
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Conditions
- Refractory Malignant Peripheral Nerve Sheath TumorEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmDesmoplastic Small Round Cell TumorRecurrent Malignant Peripheral Nerve Sheath TumorRefractory Desmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Malignant Solid Neoplasm
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04530487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- Conditions
- Central Nervous System Germ Cell TumorMalignant GliomaPrimitive Neuroectodermal TumorRecurrent MedulloblastomaAnaplastic EpendymomaAtypical Teratoid/Rhabdoid TumorIntracranial Myeloid SarcomaRecurrent Anaplastic EpendymomaRecurrent Primitive Neuroectodermal TumorChoroid Plexus Carcinoma
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04521946
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
- Conditions
- Hematologic MalignancyHematologic DiseasesAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia
- Interventions
- Device: CliniMACSProcedure: Bone Marrow TransplantDrug: Hyperfractionated Total Body Irradiation
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT04282174
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- High-Risk NeuroblastomaPatient With Insufficient Response Chemoimmunotherapy
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
- Conditions
- Acute Myeloid LeukaemiaHigh-risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 333
- Registration Number
- NCT04217278
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧Manchester Royal Infirmary, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.